Detalhe da pesquisa
1.
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
Blood
; 138(3): 213-220, 2021 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292324
2.
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Blood
; 137(16): 2161-2170, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33171487
3.
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
Cancer
; 128(7): 1411-1417, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34931301
4.
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
Blood
; 134(17): 1395-1405, 2019 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31471376
5.
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Blood
; 131(19): 2120-2124, 2018 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29507077
6.
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.
Acta Haematol
; 143(1): 40-50, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31315113
7.
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Cancer
; 125(9): 1507-1517, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30694529
8.
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.
Am J Hematol
; 94(6): 641-649, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30896890
9.
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
Br J Haematol
; 183(4): 601-607, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30596402
10.
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project.
Haematologica
; 103(7): 1191-1197, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29599200
11.
Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
Am J Hematol
; 93(4): 546-552, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29318644
12.
A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.
Cancer
; 123(7): 1174-1183, 2017 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27911989
13.
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
Biol Blood Marrow Transplant
; 22(2): 380-385, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26348890
14.
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Br J Haematol
; 172(4): 535-44, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26627450
15.
Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting.
Clin Trials
; 13(5): 545-54, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27154912
16.
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.
Br J Haematol
; 171(5): 788-97, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26455717
17.
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
Hematol Oncol
; 33(4): 187-91, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25236531
18.
A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.
Br J Haematol
; 186(1): 159-162, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30592026
19.
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Blood
; 119(18): 4115-22, 2012 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-22394596
20.
Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.
Am J Hematol
; 94(4): E117-E116, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30663774